MABD42
Anti-Cyp7a1 Antibody, clone 15B9.1
clone 15B9.1, from mouse
Synonym(s):
Cholesterol 7-alpha-monooxygenase, CYPVII, Cholesterol 7-alpha-hydroxylase, Cytochrome P450 7A1
Sign Into View Organizational & Contract Pricing
All Photos(5)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
15B9.1, monoclonal
species reactivity
rat, mouse, human
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG2aκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CYP7A1(1581)
General description
Cytochrome P450 7A1 (CYP7A1, CYPVII), also known as cholesterol 7-alpha-monooxygenase or cholesterol 7-alpha-hydroxylase, belongs to the cytochrome P450 family and is important for cholesterol homeostasis. CYP7A1 catalyzes a rate-limiting step in cholesterol catabolism and bile acid biosynthesis by introducing a hydrophilic moiety at position 7 of cholesterol. Detected primarily in the liver, CYP7A1 catalyzes the following reaction: Cholesterol + NADPH + O2 = 7-alpha-hydroxycholesterol + NADP+ + H2O. CYP7A1 is up-regulated by glucose and by cholestyramine, and is down-regulated by chenodeoxycholic acid.
Immunogen
GST-tagged recombinant protein corresponding to human Cyp7a1.
Application
Imunnohistochemistry Analysis: A 1:50-1,000 dilution from a representative lot detected Cyp7a1 in rat and human liver tissue.
Research Category
Apoptosis & Cancer
Apoptosis & Cancer
Research Sub Category
Apoptosis - Additional
Apoptosis - Additional
This Cyp7a1 antibody is validated for use in WB & IHC for the detection of the Cyp7a1 protein.
Quality
Evaluated by Western Blotting in human liver tissue lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected Cyp7a1 in 10 µg of human liver tissue lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected Cyp7a1 in 10 µg of human liver tissue lysate.
Target description
~52 kDa observed
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
Human liver tissue lysate
Human liver tissue lysate
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yongtao Xiao et al.
Cell death & disease, 8(10), e3110-e3110 (2017-10-13)
The p38α mitogen-activated protein kinase (MAPK) has been related to gluconeogenesis and lipid metabolism. However, the roles and related mechanisms of p38α MAPK in intestinal failure (IF)-associated liver steatosis remained poor understood. Here, our experimental evidence suggested that p38α MAPK
Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.
Hana Lastuvkova et al.
International journal of molecular sciences, 22(12) (2021-07-03)
Bile acids (BA) play a significant role in the pathophysiology of nonalcoholic steatohepatitis (NASH). The present study evaluates the modulation of bile acid metabolomics by atorvastatin, a cholesterol-lowering agent commonly used to treat cardiovascular complications accompanying NASH. NASH was induced
Mao-Xu Ge et al.
Acta pharmacologica Sinica, 40(7), 895-907 (2018-12-24)
The manipulation of bile acid (BA) homeostasis by blocking the ileal apical Na+-dependent bile salt transporter (ASBT/SLC10A2) may have therapeutic effects in nonalcoholic fatty liver disease. We developed a novel ASBT inhibitor, an N-(3,4-o-dichlorophenyl)-2-(3-trifluoromethoxy) benzamide derivative referred to as IMB17-15
Arvin Iracheta-Vellve et al.
Hepatology communications, 2(11), 1379-1391 (2018-11-10)
Bile acids (BAs) activate various dedicated receptors, including the farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5). The FXR agonist obeticholic acid (OCA) is licensed for the treatment of primary biliary cholangitis and has shown promising
Takeshi Katsuda et al.
FEBS letters, 594(1), 114-125 (2019-08-23)
The immediate deterioration of primary human hepatocytes (PHHs) during culture limits their utility in drug discovery studies. Here, we report that a cocktail of four small molecule signaling inhibitors, termed YPAC, is useful for maintaining various hepatic functions of PHHs
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service